Arbutus Q2 FY26 net loss widens to $5.1 million; revenue drops 90.56% to $1.01 million
PUBT·- Arbutus Biopharma reported a Q2 FY26 net loss of $5.1 million and a 90.56% revenue drop to $1.01 million. - The company reduced R&D expenses by 47.27% to $2.9 million and held $92.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026. - Arbutus plans to repurchase up to about $230 million of shares starting in Q3 and has filed international patent enforcement suits against Pfizer and BioNTech.Arbutus files patent infringement suits against Pfizer, BioNTech over LNP technology
PUBT·- Arbutus Biopharma has filed patent infringement suits against Pfizer and BioNTech in Canada and Europe, concerning its lipid nanoparticle technology. - The lawsuits seek damages and injunctions related to the mRNA-LNP COVID-19 vaccines, targeting specific patents in multiple jurisdictions. - Following a settlement with Moderna, Arbutus plans to initiate share repurchases of about USD 230 million in Q3 2026, dependent on a potential dividend from Genevant.